Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment
F Kreidieh, I Abou Dalle, N Moukalled… - International Journal of …, 2022 - Springer
Despite therapeutic progress in acute myeloid leukemia (AML), relapse post-allogeneic
hematopoietic stem cell transplantation (allo-HSCT) remains a major challenge. Here, we …
hematopoietic stem cell transplantation (allo-HSCT) remains a major challenge. Here, we …
Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement
M Di Nardo, G MacLaren, P Schellongowski… - The Lancet …, 2023 - thelancet.com
Combined advances in haematopoietic cell transplantation (HCT) and intensive care
management have improved the survival of patients with haematological malignancies …
management have improved the survival of patients with haematological malignancies …
[HTML][HTML] Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
C Zhang, XQ Wang, RL Zhang, F Liu, Y Wang, ZL Yan… - Leukemia, 2021 - nature.com
Safety and efficacy of allogeneic anti-CD19 chimeric antigen receptor T cells (CAR-T cells)
in persons with CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) relapsing after …
in persons with CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) relapsing after …
[HTML][HTML] Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell …
L Axt, A Naumann, J Toennies, SP Haen… - Bone Marrow …, 2019 - nature.com
Acute and chronic graft-vs.-host disease (aGvHD and cGvHD) are major complications after
allogeneic hematopoietic cell transplantation (HCT) leading to substantial morbidity and …
allogeneic hematopoietic cell transplantation (HCT) leading to substantial morbidity and …
Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European …
Although second allogeneic haematopoietic cell transplantation (allo‐HCT 2) is a
therapeutic option for patients relapsing after first HCT (allo‐HCT 1), there is limited data on …
therapeutic option for patients relapsing after first HCT (allo‐HCT 1), there is limited data on …
Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia
M Qayed, M Bleakley, NN Shah - Current opinion in hematology, 2021 - journals.lww.com
Role of chimeric antigen receptor T-cell therapy: bridge to... : Current Opinion in Hematology
Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone …
Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone …
Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic …
X Tan, X Wang, C Zhang, X Zhao, H Yao, G Chen… - Current Medical …, 2023 - Springer
Objective This study aimed to compare the efficacy of anti-CD19 chimeric antigen receptor T
cells (CAR-T cells) versus chemotherapy plus donor lymphocyte infusion (chemo-DLI) for …
cells (CAR-T cells) versus chemotherapy plus donor lymphocyte infusion (chemo-DLI) for …
[HTML][HTML] Efficacy of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia: results of a systematic review and meta-analysis
MA Kharfan-Dabaja, T Reljic, F Yassine… - … and Cellular Therapy, 2022 - Elsevier
Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only known treatment
modality that can offer the possibility of cure for acute myeloid leukemia (AML) …
modality that can offer the possibility of cure for acute myeloid leukemia (AML) …
G‐CSF administration prior to donor lymphocyte apheresis promotes anti‐leukaemic effects in allogeneic HCT patients
C Schneidawind, S Jahnke… - British Journal of …, 2019 - Wiley Online Library
Donor lymphocyte infusion (DLI) is an effective method to establish full donor chimerism or
to prevent and treat relapse after allogeneic haematopoietic cell transplantation (allo‐HCT) …
to prevent and treat relapse after allogeneic haematopoietic cell transplantation (allo‐HCT) …
[HTML][HTML] Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter …
J Finke, C Schmoor, M Stelljes, A Burchert… - Bone Marrow …, 2022 - nature.com
Therapeutic options for patients with AML relapsing after allogeneic HCT range from
chemotherapy or hypomethylating agents with or without donor lymphocyte infusions to a …
chemotherapy or hypomethylating agents with or without donor lymphocyte infusions to a …